Moleculin Biotech Stock Target Price and Analyst Consensus

MBRX
 Stock
  

USD 1.53  0.06  4.08%   

The current analyst and expert consensus on Moleculin Biotech is Strong Buy, with 0 strong sell and 3 strong buy opinions. The current projected Moleculin Biotech target price consensus is 19.0 with 3 analyst opinions. The most common way Moleculin Biotech analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Moleculin Biotech executives and customers to further validate their buy or sell advice. Please note, the number of analysts providing the opinion is not sufficient to provide adequate consensus on Moleculin Biotech. We encourage you to use your own analysis of Moleculin Biotech to validate this buy or sell advice. Moleculin Biotech buy-or-sell recommendation module provides average expert sentiment on the projected Moleculin Biotech target price to derive its highest and lowest estimates based on projected price volatility of 9.539. Additionally, see Macroaxis Advice on Moleculin Biotech to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.
  
Refresh
Profit Margin is likely to drop to -8.54 in 2022. Moleculin Biotech Accumulated Other Comprehensive Income is fairly stable at the moment as compared to the past year. Moleculin Biotech reported Accumulated Other Comprehensive Income of 41,000 in 2021. Total Assets is likely to rise to about 90.7 M in 2022, whereas Accounts Payable is likely to drop slightly above 1.2 M in 2022.

Moleculin Biotech Target Price Consensus

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Moleculin target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Moleculin target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Number of Opinions3
Lowered Outlook0
Raized Outlook0
Strong Buy
Most Moleculin analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Moleculin stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Moleculin Biotech, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Moleculin Biotech Target Price Projection

Moleculin Biotech's current and average target prices are 1.53 and 19.00, respectively. The current price of Moleculin Biotech is the price at which Moleculin Biotech CS is currently trading. On the other hand, Moleculin Biotech's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Moleculin Biotech Market Quote on 5th of July 2022

Low Price1.41Odds
High Price1.55Odds

1.53

Target Price

Analyst Consensus On Moleculin Biotech Target Price

Low Estimate10.0Odds
High Estimate29.0Odds
Number of Analysts3
Standard Deviation9.539

19.0

Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Moleculin Biotech CS and the information provided on this page.

Moleculin Biotech Analyst Ratings

Moleculin Biotech's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Moleculin Biotech stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Moleculin Biotech's financials, market performance, and future outlook by experienced professionals. Moleculin Biotech's historical ratings below, therefore, can serve as a valuable tool for investors.

Analyst Consensus Breakdown

Average Consensus Estimates

About Moleculin Biotech Target Price Projections

Moleculin Biotech's target price is an analyst's projection of its future price. Price targets can be assigned to all types of securities, from complex investment products to stocks such as Moleculin Biotech and even bonds. If the target price is unavailable, it is most likely because there were not enough analyst opinions to come up with a consensus estimate. When setting a price target estimate, an analyst is trying to determine what the Stock is worth and where the price will be in a year from now. Generally, the target price of Moleculin depends on its intrinsic valuation, beta (i.e., risk over market), and overall volatility. Most analysts publish their price targets in research reports on specific companies, along with their buy, hold, or sell recommendations. Stock price targets are often quoted in the financial news media. Macroaxis uses multiple feeds to provide overall target price projection for Moleculin Biotech CS including its fundamental analysis.

Additional Moleculin Biotech Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Moleculin Biotech is a key component of Moleculin Biotech valuation and have some predictive power on the future returns of a Moleculin Biotech.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Moleculin Biotech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Moleculin Biotech in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
0.071.485.38
Details
Intrinsic
Valuation
LowReal ValueHigh
1.325.789.68
Details
Naive
Forecast
LowNext ValueHigh
0.031411.575.47
Details
Earnings
Estimates (2)
LowProjected EPSHigh
-0.79-0.71-0.63
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Moleculin Biotech. Your research has to be compared to or analyzed against Moleculin Biotech's peers to derive any actionable benefits. When done correctly, Moleculin Biotech's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Moleculin Biotech.

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Macroaxis Index
Invested few shares
Cancer Fighters
Invested few shares
Additionally, see Macroaxis Advice on Moleculin Biotech to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
The data published in Moleculin Biotech's official financial statements usually reflect Moleculin Biotech's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Moleculin Biotech. For example, before you start analyzing numbers published by Moleculin accountants, it's critical to develop an understanding of what Moleculin Biotech's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Moleculin Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Moleculin Biotech's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Moleculin Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Moleculin Biotech CS. Please utilize our Beneish M Score to check the likelihood of Moleculin Biotech's management to manipulate its earnings.